Journal of Urban Health: Bulletin of the New York Academy of Medicine, Vol. 81, No. 3,
The New York Academy of Medicine 2004; all rights reserved.
doi:10.1093/jurban/jth128
Injection Drug Use and the Hepatitis C Virus:
Considerations for a Targeted Treatment
Approach—The Case Study of Canada
Benedikt Fischer, Emma Haydon, Jürgen Rehm,
Mel Krajden, and Jens Reimer
ABSTRACT Infection with the hepatitis C virus (HCV) is a major public health burden
in Canada and globally. The literature shows that injection drug use is currently the
primary transmission route for HCV, and that a majority of injection drug users
(IDUs) are currently infected with HCV in Canada. This article first reviews the burden of HCV within IDU populations and the transmission risks and the treatment
implications specific to IDUs. Traditionally, IDUs have been excluded from HCV
treatment unless abstaining from illicit drug use. However, recent research suggests
that categorical exclusion is not medically necessary. A series of key questions about
the feasibility of offering HCV treatment to IDUs in the specific Canadian context are
considered, including concerns related to the motivation of treatment for IDUs, treatment
delivery, treatment side effects, HCV reinfection, and the social environment. The article concludes that treatment of HCV-infected illicit drug users is both feasible and may
be necessary to reduce transmission and adverse outcomes in this high-risk population.
KEYWORDS
Canada, Hepatitis C, Injection drug use, Prevention, Treatment.
INTRODUCTION
Infection with the hepatitis C virus (HCV) and related disease consequences constitute
a major health burden in Canada as well as globally.1–3 This situation is aggravated
by the fact that the major health consequences of HCV infection—including liver
cirrhosis and hepatocellular carcinoma—do not, in many cases, materialize until
years or decades after infection. Among the various risk factors for HCV in Canada,
injection drug use has emerged as the primary transmission route. Furthermore, the
majority of injection drug users (IDUs) appear to be infected with HCV, and the
majority of new HCV infections can be attributed to injection drug use.4,5
In this article, we first give a brief overview of HCV risk and epidemiology as it
relates to IDUs in the Canadian context. We then outline HCV transmission risk
factors within populations of IDUs, followed by a discussion of treatment implications
and barriers. Finally, we outline a set of questions and challenges specific to the
Drs. Fischer and Rehm are with the Department of Public Health Sciences, University of Toronto,
Ontario, Canada; Drs. Fischer and Rehm and Ms. Haydon are with Public Health and Regulatory Policy
Research Section, Centre for Addiction and Mental Health, Toronto, Ontario, Canada; Dr. Krajden is
with British Columbia Hepatitis Services, and with Pathology and Laboratory Medicine, University of
British Columbia, both in Vancouver, British Columbia, Canada; and Dr. Reimer is with the Center for
Interdisciplinary Addiction Research, Hamburg, Germany.
Correspondence: Dr. Benedikt Fischer, Centre for Addiction and Mental Health, 33 Russell Street,
Room 2035, Toronto, ON M5S 2S1, Canada. (E-mail: benedikt_fischer@camh.net)
428
INJECTION DRUG USE AND HEPATITIS C
429
target population of IDUs that will need to be addressed to facilitate much-needed
targeted HCV treatment options.
THE HEPATITIS C VIRUS BURDEN
General Population
About 170 million persons worldwide (3% of the global population) are infected with
the HCV.6 If not treated, the infection becomes chronic in 50% to 85% of individuals;
10% to 20% of infected persons develop liver cirrhosis within 10–20 years of infection, and 5% to 10% of those with cirrhosis develop hepatocellular carcinoma.7,8
In Canada, it is estimated that 0.8%–1.0% of the total population, or 250,000–
315,000 persons, are HCV infected.1,9 Regional variations exist, with peak HCV prevalence rates in the three largest provinces (British Columbia, Ontario, Quebec).1 Prediction models of the future HCV-related burden of illness in Canada suggest that
approximately 4,000 new HCV infection cases are expected each year.10 Estimates propose that the number of patients with HCV-related cirrhosis, liver failure, and hepatocellular carcinoma will likely double by the year 2008; simultaneously, it is expected
that the number of HCV-related liver deaths would more than double in that period.1,9,10
The HCV-related health care costs have been estimated at $500 million per annum in
Canada to date; by 2010, this cost burden is expected to reach $1 billion (M. Krajden,
personal communication, 2002). Similar proportions of the burden of illness related to
HCV exists for the United States, where 2.7 million persons have chronic HCV infection; for the period 2010–2019, estimates predict 165,000 deaths from liver disease,
27,000 deaths from hepatocellular carcinoma, $10.7 billion in direct medical expenditures, and societal costs of $75.5 billion in lost productivity related to HCV.11
Injection Drug User Populations
IDUs are at particular risk of HCV exposure and infection, related in large part to the
method of drug administration that defines the population. For the purposes of this article, injection drug use refers to the injection of any illicit drug, mainly opiates, cocaine,
crack, and amphetamines, although IDUs can employ variable routes of drug administration.12 Although the drugs used by IDUs may be different, there are certain HCV
transmission-related risks and characteristics that appear regardless of the drug injected.
The two major transmission routes responsible for the majority of previous and
existing HCV infections in Canada have been therapeutic blood receipt and injection drug use.4 As detection of HCV infection in donated blood and tissue samples
has improved substantially and prevention measures have been established, injection drug use remains the single major risk factor for HCV transmission. Between
one half and two thirds of HCV infections in Canada are thought to be caused by
injection drug use.4,5 A small proportion of the remaining cases of HCV transmission
are thought to be attributable to sexual transmission, needle-stick accidents, and
tattooing.3,13,14 Although discussion of drug use as a risk for HCV transmission is
usually limited to “injection,” other forms of drug administration involving the
exchange of blood (intranasal cocaine use and crack smoking) have been identified
as possible transmission routes.13–16 Even in light of the evidence pointing toward
injection drug use as the primary risk factor for HCV transmission, IDUs remain a
relatively understudied population of those with chronic HCV infection.17
Within the high-risk population of IDUs in other Western countries, numerous
studies18 have demonstrated anti-HCV positivity rates of 60% to 95%. One of the
430
FISCHER ET AL.
strongest predictors of anti-HCV positivity is the duration of injection drug use.19–28 In
an ongoing cohort study of untreated illicit opiate users in five cities across Canada,
saliva tests indicated 61% anti-HCV positivity.29 Other evidence of the high rates of
anti-HCV comes from specific Canadian cities. For example, a cohort of 1,345 injection
drug users in Vancouver (Vancouver cohort study of IDUs, VIDUS) demonstrated
that 81.6% were anti-HCV positive at recruitment; over a 3-year follow-up period
(1996–1999), the originally seronegative cases demonstrated an incidence rate of over
16 per 100 person-years.30 An open cohort of IDUs in Montreal indicated a 70% antiHCV prevalence rate,31 and a Toronto cohort of untreated illicit opiate users selfreported a 56% anti-HCV positivity rate.32 A cohort of drug injecting youth in
Vancouver indicated 46% anti-HCV prevalence at baseline,33 and injection drug user
populations in Calgary and Winnipeg have indicated anti-HCV prevalence rates of
56% and 60%, respectively.34
INJECTION DRUG USERS AS A DISTINCT HIGH-RISK GROUP
FOR HEPATITIS C VIRUS
Direct and indirect characteristics and determinants render IDUs a distinct population
from the perspective of HCV transmission risk and treatment implications. The
determinants related to the high risk of HCV transmission for IDUs are presented in the
next section. This is followed by a review of injection drug use–specific HCV treatment challenges. Canadian data are reported if applicable and/or available.
Hepatitis C Virus Transmission Risk
Overall, IDUs are a distinct risk population for HCV because they have chronic
exposure to the virus, are engaged in specific risk behaviors facilitating HCV transmission, and are in a particular social context that increases risk of transmission.
Drug Use and Injection Risks Because blood-to-blood contact is the main mode
of transmission for HCV infection, a variety of distinct risk factors exists for IDUs
in relation to the route of drug administration: injection. The main risk factor for
HCV transmission has been shown to be the sharing of contaminated needles and
other drug use paraphernalia; front- and backloading, communal mixing and
drawing into syringes from the same bags, as well as “booting” and “jacking”
(drawing blood into a syringe before injecting) also increase the possibility of
blood-to-blood contact.2,3,35–38 HCV may be transmitted more efficiently than
human immunodeficiency virus (HIV) as it exhibits higher infectivity,39 increasing
the risks of sharing contaminated injection equipment.37,40
Although not all IDUs share needles, the practice is quite common; in one
study, 33% of untreated illicit opiate users in Toronto reported having shared needles, and 41% of respondents had shared other works in the last year.32 In VIDUS,
of 776 participants who reported active injection drug use in the 6 months before
the most recent follow-up, during the period January 1999 to October 2000, there
were 27% who reported sharing needles during the 6-month period.41
Daily injection, sharing needles, cocaine injection (which is typically more frequent), and a history of drug treatment have been shown to be significantly correlated
with anti-HCV positivity.42 Sharing of injection equipment other than needles is also
an important risk factor because blood particles are contained in both syringes and
other injection paraphernalia.27 One study found that 54% of HCV infections in
IDUs who did not share needles were attributable to cooker/cotton sharing.27
INJECTION DRUG USE AND HEPATITIS C
431
Skin infections related to injection, including abscesses and other open wounds,
are also common in IDUs.12 Open wounds on the skin may enhance the transmission
of HCV through direct contact with infected blood. Also, IDUs who engage in
crack smoking can develop oral sores from burns or cuts,43 which may increase
HCV transmission risk through oral crack use paraphernalia.
Especially among cocaine-using IDUs, the number of injections per day can
be very high, with up to 30 injection episodes during “binge” days; therefore, their
risk of blood contact is likely higher than for heroin or amphetamine injectors.38,44
The VIDUS study in Vancouver found that frequent cocaine injection was also
associated with needle sharing.41 Cocaine use, injection, and the use of needleexchange programs were key factors associated with the seroconversion to antiHCV-positive status of IDUs in a Vancouver cohort.30 Frequent injection, together
with the above-described injection risks, increases the probability of blood contact,
thereby enhancing HCV transmission risks.
However, knowledge of serostatus may alter injection and drug use risk behaviors.
A recent study found that 61% of the sample of 197 out-of-treatment IDUs in
Denver, CO, were unaware that they were anti-HCV positive. Participants who
were unaware of their anti-HCV-positive status were more likely to share equipment,
inject with used needles, and report unsafe injection practices.45
Biological Risks A number of possible immunological determinants that increase
HCV transmission risk are present in populations of IDUs. IDUs, especially those
also involved in cocaine/crack and polydrug use may be significantly affected by
decreased immunocompetence.42,46–49 Increased stress and blood cortisol levels—
related to injection drug use behaviors—have been recognized as variables compromising immunity in IDUs.50,51 Decreased immunocompetence may have an impact
on the body’s ability to act against exposure to HCV, which is important in light of
the high rate of exposure of IDUs to HCV-contaminated blood. However, there
are also indications that IDUs may exhibit decreased susceptibility to HCV52
because of their repeated exposure to the virus, although the evidence on this is
still unclear.18,53,54
Possible relevant interactions between HCV and other infectious virological diseases have been suggested to occur, with many infectious diseases more common
among those with HCV infection in comparison to those without HCV infection.55
Interactions with HIV have been shown to occur on the immunological level, with
HIV-infected individuals exhibiting accelerated adverse outcomes and the possibility
of increased risk of HCV infection in the presence of HIV.43,56,57 Also, HCV infection
is more prevalent in alcoholics,58,59 and alcohol dependence is common in illicit drug
users60; thus, IDUs consuming alcohol are at increased risk. There are thus a number of biological factors, most relating to immunosuppression, that may lead to
enhanced HCV infectivity in IDUs.
Physical Health Risks IDUs, especially those with a long-term drug use history,
in general tend to display a poorer health status.12 In a Toronto cohort of
untreated illicit opiate users, with a majority of IDUs, 54% of participants reported
that they were currently experiencing severe health problems, and 33% reported
having been hospitalized in the last 12 months.32 Studies of illicit drug user populations across Canada reported disproportionately high frequencies of medical visits
to emergency rooms or physicians; conversely, illicit drug users report a high
frequency of medical emergency situations in which required medical help was not
432
FISCHER ET AL.
available or accessible.32,61,62 Disproportionate levels of compromised physical
health of IDUs may be related in part to greater susceptibility of HCV infection and
thus the high rate of HCV within populations of IDUs.
Sexual Risks Another risk factor for HCV infection common in IDUs is the disproportionate involvement of the this population in sex trade work and high-risk
sexual activities. Although risk for HCV through sexual transmission is low, HCV
can be transmitted through high-risk sexual activities, such as unprotected sex, and
is exacerbated by sexual contact with multiple partners4; such individuals are also at
increased risk of acquiring sexually transmitted infections.63 A study of patients
(N = 6,668) of sexually transmitted disease clinics in Edmonton found that engaging
in prostitution or trading sex for drugs and not using condoms were significant risk
factors for anti-HCV positivity.64 IDUs have also been reported to be more likely
than noninjecting drug users to engage in sex trading.65 One study also found a
correlation between receiving money for sex and anti-HCV positivity in a sample of
IDUs in Harlem, New York28; similarly, selling sex was reported as an independent
risk factor for anti-HCV seroconversion in a sample of young IDUs in San Francisco,
California.37 In the Toronto sample of untreated illicit opiate users mentioned here,
31% had engaged in unprotected vaginal or anal intercourse in the past year.32 In a
sample of IDUs in Toronto, respondents always used condoms more often with clients
(53%) than with casual sexual partners (30%).66
Illegal shooting galleries and crack houses often have areas set aside for sexual
activities,67 which may further exacerbate the risk of sexually transmitted infections
and HCV. Ethnographic data have observed how some IDUs will beg with offers of
sex for small amounts of drugs.38 This practice enhances the risk of HCV because the
individual may engage in unprotected sex, and the drug received in return may be
what was left over after the drug “giver” had already done his or her injection. Highrisk sexual activities are also documented in crack users, specifically involving multiple partners, trading sex for money or drugs, and inconsistent use of condoms.60,68,69
Social Factors Poor health, lack of social integration, poverty, gender issues, and
inadequate access to health services are important risk factors for disease in the
general population,70 and these risk dynamics are further exacerbated in populations of IDUs.71 In a cocaine-using sample in Vancouver, those with unstable
housing conditions were significantly more likely to use emergency room services,62
suggesting a poorer health status for those more economically disadvantaged. Social
marginalization—as is, for example, reflected by poverty and poor housing frequent
among IDUs in Canada and worldwide61,72,73—is correlated with higher prevalence
of HCV risks or infection.2
For example, economic disadvantage has also been suggested as contributing
to continued drug use,74,75 and there is evidence that economic deprivation leads
to sharing behaviors vis-à-vis syringes, other equipment, and drugs.76,77 The pooling of money to purchase drugs has been found to correlate with HCV seropositivity.37 A few studies have also suggested that unstable housing or lack of a
“home” or safe private space is correlated with injection risk and public injection.32,78,79 Many subjects in the study of illicit opiate users in Toronto had
injected in outdoor or semipublic areas (including streets, cars, and alleyways).32
Outdoor injection has been shown to be correlated with the reuse of needles not
cleaned by bleach,80 although the utility of bleach cleaning in the prevention of
HCV transmission is still unclear.
INJECTION DRUG USE AND HEPATITIS C
433
Certain sociodemographic variables have also been suggested to influence
risk in IDUs, including gender (women more at risk of sharing because of the
nature of their social relationships)77,81 and racial or ethnic status.79,82,83
TREATMENT IMPLICATIONS
Although the pharmacotherapeutic treatment of HCV in general populations has
made great progress in recent years,84,85 there are still a number of key dynamics and
characteristics of HCV treatment that are specifically relevant for IDUs and need to
be considered to ensure feasibility of HCV treatment in this population.
One important consideration is the differential treatment duration and
response, which are dependent on the infecting HCV genotype. There are at least
six major HCV genotypes and several subtypes, which differ in their geographic
distribution.86 Genotypes 1, 2, and 3 are the most common in North America.86,87
Genotypes 1 and 3 are more prevalent in IDUs,35,88–90 although different patterns are
observed worldwide.22,91 Although HCV genotypes are generally not related to
disease severity,87–89,92 they do affect treatment duration and response. Genotype 1
requires a 48-week course of pegylated interferon/ribavirin therapy with a 40%–
46% probability of sustained viral clearance; in contrast, genotypes 2 and 3 require 24
weeks of therapy, and approximately 76%–82% of treated people respond.46,93–95
Therefore, knowledge of genotype is required to guide treatment duration and
response.
Potential drug interactions also need to be considered. For example, it has been
suggested96 that interferon and pegylated interferon (peginterferon) can lead to an
increase in serum methadone levels, especially in the presence of alcohol. This is
especially important for illicit opiate users who may begin HCV treatment in the
context of a methadone program. Also, there is evidence that alcohol use decreases
treatment response rates to interferon therapy.97
Psychiatric comorbidity status and susceptibility are also key concerns for possible HCV treatment, primarily focusing on the frequent and often severe neuropsychiatric (mostly depression, but also psychosis) side effects of interferon therapy
regimes. Psychiatric comorbidity (i.e., depression, anxiety disorders, and psychosis)
is disproportionately prevalent in drug user populations.98–104 In fact, many illicit
drug users have been shown to engage in substance use as a form of self-medication
for psychiatric conditions.105–107 HCV treatment and its potential psychiatric side
effects may thus initiate a vicious cycle exacerbating drug use and its related risks in
this population.108
Although IDUs may disproportionately seek or access certain health care
services (particularly emergency services), they also experience barriers to adequate
preventive and nonemergency care, including issues of trust and stigma in relation
to health care providers, fear of detection of illicit drug use and punitive consequences, and the inability to enter the health care system without a primary physician.32,71 In Australia, HCV-related dynamics of discrimination within the health
care system have been recognized as a barrier to HCV treatment access for IDUs
and other illicit drug users.109,110 A study of Seattle, Washington, IDUs found that
HCV reporting to public health services for the sample was extremely low, and the
authors suggested the reasons for this were related in part to the poor access of
IDUs to the health care system.111 Thus, a number of treatment issues specific to
IDU populations will need to be addressed if HCV treatment is to be provided in an
effective manner.
434
FISCHER ET AL.
Previous State of Hepatitis C Virus Treatment for
Injection Drug Users
Until recently, both Canada and the United States suggested that HCV treatment
for illicit drug users was not recommended.112 In the United States, for example, it
was advocated113 that “[HCV] treatment of patients . . . who are actively using illicit
drugs should be delayed until these habits are discontinued for at least 6 months”
(p. 24). In Canada, a guide to HCV treatment supported by the Canadian Medical
Association114 stated that “[c]ontinued use of injected . . . street drugs will permit
re-infection with hepatitis C, so there is no point going for therapy until this habit
has been stopped” (p. 69). In an urban population of HIV and HCV co-infected
patients in Boston, Massachusetts, assessed for suitability for interferon treatment,
70% were deemed ineligible by infectious disease and hepatology staff in a medical
clinic, with active drug or alcohol use cited as one of the main reasons.115
Although the exclusion of illicit drug users from HCV treatment has been rationalized for the most part by specific “contraindications” relating to active drug use,
psychiatric comorbidity, and concerns with adherence,108,1156 the categorical barring
of illicit drug users from HCV treatment is being questioned.84,116 Rather, it can be
argued that stigma and systemic and ideological factors may reflect a populationspecific form of discrimination117 that leads to IDUs being denied treatment.112,118
New Hepatitis C Virus Treatment: The Chance for
Hepatitis C Virus Treatment for Injection Drug Users?
Over recent years, the new generation of pharmacotherapeutic treatments—specifically
peginterferon in combination with ribavirin—has become established as a substantively improved form of therapy for HCV.119,120 The treatment regimes have already
been described in the section relating to treatment implications for IDUs.
Pegylated interferon by injection can be administered once a week, thus easing
compliance and medical visit requirements.84 Psychiatric side effects of this therapy
have also been reduced in severity.121 The fact that sustained virological responders
clear the virus completely from the body has led to the optimistic conclusion that
HCV has become a “curable disease.”122 Therefore, treatment should be made
widely available and accessible to those infected to reduce individual and social burden
related to HCV infection. Interferon-plus-ribavirin therapy for HCV has also been
determined to be a cost-effective approach to treating chronic HCV.123–125
A few encouraging HCV treatment studies have been successfully conducted
with the special target population of IDUs. The Table provides data regarding the
evaluation of HCV treatment in a selection of studies with samples of illicit drug
users. Positive results were found in an experimental HCV treatment study of drug
users, with a 36% sustained viral response rate when treated with interferon or
interferon/ribavirin combination therapy, regardless of success in the substance use
detoxification program.126,127 An Italian study of newly detoxified heroin users
(within 2–4 weeks of detoxification treatment) found an enhanced response to
interferon alfa-n2b treatment (8 weeks of treatment) for the user group in comparison to controls without a history of drug addiction, although there were no data
on sustained virological response.128
An evaluation study of the safety, tolerability, and efficacy of interferon/ribavirin
combination therapy in HCV-infected illicit opiate injector patients engaged in
methadone maintenance treatment found that the end-of-treatment response rate
was similar to that of patients without a history of illicit drug use.129 Researchers in
Munich conducted a study of treatment with interferon alfa plus ribavirin for
TABLE. Summary of published studies on treatment of chronic hepatitis C in injection drug users
Reference
Treatment setting
Antiviral treatment
Number treated
126, 127
128
131
In-/outpatient detoxification
Inpatient detoxification
Outpatient methadone substitution
and unspecific
Interferon or interferon/ribavirin combination
Interferon
Interferon/ribavirin combination
50
47
42
130
Outpatient methadone
maintenance
Interferon/ribavirin combination
50
Sustained virological response
(percentage of patients)
36%
Not determined
43% in the methadone substitution
group 28% in the former addiction
group
54%
435
436
FISCHER ET AL.
psychiatric risk groups (n = 81), including psychiatric patients, methadone treatment
clients, patients with former addictions, and a control group.130 Virological
response of those with drug use histories was comparable to that of the psychiatric
and the control groups, although the former addiction group did have significantly
higher dropout rates.
A Norwegian study131 provided 5-year follow-up data on 27 IDUs treated
successfully (sustained virological response) for chronic HCV infection with interferon
alpha with or without ribavirin, with all but one remaining HCV-RNA (ribonucleic
acid) negative at the follow-up point of 5 years after treatment. However, this study
required patients to be illicit drug use free for at least 6 months prior to HCV treatment
and did not provide follow-up data on the viral nonresponders.
Although the data for these studies are encouraging, the small sample sizes
make conclusions on widespread feasibility and effectiveness of HCV treatment for
drug users premature. Given that IDUs are currently the major risk population for
HCV infection and related disease, the crucial questions are whether these advances
in HCV treatment can be generalized into an opportunity for broad-scale HCV
treatment for IDUs as well as whether, subsequent to the initiation of treatment,
ways can be found to reduce HCV transmission risk in this target population. It
indeed seems that the time has come for a targeted and proactive HCV treatment
approach for IDUs, and that it is feasible and desirable from a public health perspective. However, the complexity of the problem as well as particular characteristics and needs of the target population of drug users—regarding HCV treatment as
well as posttreatment prevention—leave some key challenges for wide-scale operationalization as well as knowledge gaps that require addressing for a fully evidencebased HCV treatment campaign for IDUs.
In the following, we outline and discuss key challenges and issues relating to
HCV treatment of IDUs:
Are IDUs Interested in and Motivated for Hepatitis C Virus Treatment? One cannot categorically assume that HCV-infected IDUs are interested in and motivated for
HCV treatment even if it were widely available and accessible. First, many IDUs are
not aware of their HCV status45 or are not interesting in knowing. Second, the lives
of IDUs are chaotic and described by short-term existential needs and concerns,132
including the need to obtain drugs and funds to buy drugs, being at risk of death or
disease from multiple causes, being in conflict with the law, and frequently lack of
shelter. HCV treatment may be a low priority for IDUs, especially if there is a lack
of acute symptoms related to their HCV status, because it can be many years before
more tangible and severe disease consequences materialize. Also, to date there has
been no systematic ranking of HCV-related health consequences in the assessment of
the global burden of disease, as this has been done for HIV.133 It is therefore difficult
to gauge the rank order of HCV in relation to other health consequences related to
injection drug use. A crucial research effort would be to address this area to further
inform the need and motivation for HCV treatment in IDUs.
However, in an ongoing multisite cohort study of untreated users of illicit opiates, the majority of whom are injectors, in sites across Canada (N = 455 at preliminary analysis), 36.9% listed HCV infection and its related complications when
asked for their “primary physical health problem.”29 This figure clearly indicates
that HCV infection represents a real and tangible health problem in populations of
illicit drug users. On the other hand, there is evidence that a considerable proportion of drug users may not be interested in HCV treatment.
INJECTION DRUG USE AND HEPATITIS C
437
In Rhode Island, a survey of 306 former IDUs currently in a methadone maintenance program were asked about their willingness to receive interferon HCV treatment. After being informed of the risks and benefits of treatment, the number of
treatment injections required, probability of successful therapy, treatment side
effects, and the need for liver biopsy, only 53% indicated that they would definitely
or probably enter treatment.134
A Swiss study reported the reasons for nonparticipation in HCV treatment for
drug users deemed eligible for treatment.116 Among the 28.3% of patients who
refused the HCV treatment offered, the main reasons stated for refusal were side
effects, the need to have blood drawn, and the need to come in for regular office visits
during treatment. On the basis of the above, more information is required to gauge
IDUs’ interest and readiness for HCV treatment.
How Would Hepatitis C Virus Treatment Best Be Delivered to IDUs? Treatment for
HCV in IDUs should be initiated through an individualized approach,118 as for all
HCV infected people,112 and there should be no automatic or implicit exclusion of
IDUs from treatment.135 Important principles to consider in the operationalization
of treatment are the need for effective access and support and a trusting provider
environment.136,137 These treatment environment qualities may best be accomplished
by utilizing community organizations familiar with and adapted for the special profiles and needs of drug user clienteles. In Canada, the relatively broad availability of
needle-exchange and methadone treatment programs,138,139 especially in the urban
centers, could provide for some of the supporting infrastructure.
A related challenge for effective HCV treatment is attaining maximum adherence to the treatment regime because treatment effectiveness is directly correlated
with adherence.140 Although there are widespread assumptions that illicit drug users
are not capable of adherence to long-term pharmacotherapeutic treatment regimes,
experience regarding treatment of other infectious diseases of drug users (e.g., HIV
and tuberculosis) has demonstrated the possibility of comparably “normal” or good
compliance rates.141,142 For the most marginalized injection drug use patients, the
possibility of peginterferon monotherapy (no ribavirin) may be considered. This
treatment regime does not require the daily ribavirin component and may be
considered especially in patients with genotypes 2 and 3, for which response rates
are as high as 40%, although it is still not as effective as pegylated interferon/ribavirin treatment.120 Embedding HCV treatment into other comprehensive programs of
social, health, addiction, or treatment services that drug users trust, need, and
frequent regularly (e.g., methadone treatment or needle-exchange program) may
facilitate treatment acceptance and adherence; individualized therapy plans and
reward systems (e.g., the possibility of methadone “take-homes”) may reinforce
desired effects. HCV treatment demonstration projects for illicit drug users in
Europe and the United States using a combination of the above strategies have
shown positive initial results, with adherence rates of 80% and more.126,129
How Could Treatment Side Effects Be Managed? One of the most problematic
side effects of interferon-based treatment for HCV is psychiatric symptoms, primarily
depression or anxiety.95,143,144 It has been reported that interferon treatment has initiated such psychiatric episodes in patients with no prior psychiatric history, as well
as aggravated symptoms in people for whom they previously existed. As discussed,
a disproportionately high number of illicit drug users demonstrate psychiatric
comorbidities.145
438
FISCHER ET AL.
Self medication dynamics of drug use105–107 were discussed in this article in
relation to IDUs and psychiatric status. IDUs may experience novel or aggravated
depression symptoms as an HCV treatment side effect and attempt to compensate
for these depression effects with more of the “remedy” that exposed them to HCV
in the first place (i.e., drug use and its anticipated self-medicating effect). This may
undermine the ability for treatment efficacy and adherence and also heighten the
chances of HCV reinfection because of drug injection and related risks.
The fact that a few experimental HCV treatment studies with psychiatrically
comorbid patients have concluded that treatment is possible, safe, and acceptable
for such patients when properly monitored129,146 and that antiviral treatment does
not per se lead to increased risk of psychiatric side effects130 is encouraging. However, the challenges and range of potential consequences of psychiatric side effects
in IDUs are complex. Currently, interferon-related mild-to-moderate depression can
be managed with selective serotonin reuptake inhibitors,147 although there is no
agreement in the field whether preventive medication therapy is advisable or if the
use of antidepressants should be limited to those with symptoms.148 Many psychiatric
side effects of interferon therapy are also dose related, so individualized therapy
may affect clinical manifestations.144
A thorough assessment of other nonpsychiatric side effects of HCV treatment is
also required, including more investigation into the interactions among methadone,
alcohol, and interferon.96
How to Prevent Hepatitis C Virus Reinfection of IDUs During or After Treatment?
Possible reinfection with HCV is one of the great challenges potentially undermining the long-term success and value of HCV treatment. In IDU patients, this is a
particular challenge because the habits of IDUs related to drug use may persist during and even after successful treatment. It is certainly desirable that IDUs will
undergo addiction treatment in parallel to HCV treatment, with abstinence from
drug use—bearing the main risks of HCV transmission—the possible outcome.
However, given that addiction has been recognized as a chronic disease,149 it is
unlikely that this result will or can be accomplished in all, or even a majority, of
IDUs who are ready to undergo HCV treatment. For a comprehensive HCV treatment strategy for IDUs to work and be worthwhile, it therefore must be part of
broad secondary HCV prevention strategies targeting IDUs who are at risk for continued drug use and thus possible HCV reinfection.
A small HCV treatment study with IDUs observed rather low HCV reinfection
rates by utilizing targeted prevention.131 Comprehensive HCV reinfection prevention
strategies aimed at IDUs must build on known and existing prevention measures
(i.e., comprehensive risk education, needle exchange, peer outreach programs).150–152
Such programs should also include injection drug use risk interventions that are currently under discussion in Canada, including supervised injection facilities.153,154
Increasing knowledge of HCV for users, as delivered by targeted peer and outreach
programs, may also serve to reduce risk behaviors.155
Finally, a further important measure is that the range and diversity of available
addiction treatments, including opiate maintenance treatment for opiate-using IDUs,
which has been shown to reduce infectious disease risk and transmission.156,157
How to Improve the Social Environment for Effective Hepatitis C Virus Treatment
for Injection Drug Users? The role of social determinants and environment in
health has been evidenced,70,158,159 and it is widely documented that IDUs are subject
INJECTION DRUG USE AND HEPATITIS C
439
to numerous counterproductive socioenvironmental factors that negatively influence their health status. An HCV treatment strategy for IDUs must take into consideration the broad determinants of health to address clinical therapeutic needs.
The lack of stable housing, poverty, and lack of access to proper health and social
care all contribute to the systemic marginalization of IDUs and represent a powerful
barrier barring IDUs from effective prevention and treatment in the Canadian
context.71 One critical factor is the criminalization of most IDUs, which hinders
many from accessing care because of stigma and other systemic obstacles and may
lead to contact with an environment recognized as conducive to HCV transmission:
correctional facilities.160
One final factor, with both sociocultural and ethical implications, relates to the
social status of drug users and their “deservingness” of receiving expensive medical
treatment. In ethical, medical, and general social circles, strong resistance has been
expressed against providing drug users with treatment, especially for a disease they
were seen as having brought on themselves through their “immoral” drug use
behavior.161–163 Specifically, the categorical exclusion of illicit drug users from HCV
treatment, as it was proclaimed and practiced until recently,113,114 seems neither medically tenable nor necessary112,116,163; thus, a process of innovative education and
acculturation in professional and societal arenas must begin and be translated into
everyday attitudes and practice. An interdisciplinary focus is required to share
expertise from numerous areas, including hepatology, addiction medicine, and
social services.112
CONCLUSIONS
The prevalence of HCV among illicit drug users presents a substantial and increasing
disease burden of HCV, with significant downstream public health consequences
and an ongoing source of HCV transmission. A targeted and proactive approach to
address the availability and effectiveness of HCV treatment for IDUs in Canada is
urgently needed to determine if this can improve HCV control measures on the population level given the recent feasibility of pharmacological cure. In this article, we
have outlined what some of the challenges and needs are for IDUs in the Canadian
context.
Experimental HCV treatment studies abroad have demonstrated that HCV
treatment of illicit drug users is feasible, that it can produce similar outcomes as
with non-drug-using patients, that side effects are controllable in this population,
and that secondary prevention or treatment programs may be an appropriate and
effective vehicle of delivering HCV treatment to drug users.
Recently, the NIH Consensus Development Conference on the Management of
Hepatitis C,122 declared in the final statement:
Recent, albeit limited, experience has demonstrated the feasibility and effectiveness of treating chronic HCV in people who use illicit injection drugs. . . . Thus, it
is recommended that treatment of active [IDUs] is considered on a case-by-case
basis, and that active [injection drug use] in and of itself not be used to exclude
such patients from antiviral therapy. (p. 23)
This new consensus statement explicitly underlines the eligibility and need of IDUs
for HCV treatment and should be operationalized and evaluated in the Canadian
context. The new knowledge coming from treatment studies of IDUs must be further
440
FISCHER ET AL.
developed and assessed to determine the utility of treatment as an instrument of
reducing the HCV disease burden. However, it is clear that HCV treatment must be
part of a comprehensive harm reduction program focusing on HCV itself as well as
the wider harms of injection drug use.
Other countries have chosen to lead the way with experimental and targeted
HCV treatment initiatives for IDUs. From both a public health and an individual welfare perspective, the time is right to combine scientific knowledge and professional
action into a targeted and proactive HCV treatment approach for IDUs in Canada.
ADDENDUM
In the interest of most up-to-date information published in this journal, we would
like to refer the reader to two scientific developments that have occurred since the
above manuscript was accepted. First, Dr. Robert Remis’ recent comprehensive
estimation of HCV prevalence and incidence in Canada in 2002164 essentially confirmed the primary epidemiological contribution of illicit drug use to the HCV burden described in our paper. Second, the new Canadian Consensus Statement on
Hepatitis C was published in May 2004.165 This document represents a step forward compared to the earlier position described above, as it is recognized that “a
significant proportion of the current [HCV] infections [occur] in vulnerable populations”; further, it is claimed that “this document, unlike previous documents, does
not exclude active injection drug users from therapy,” and that “in all cases, the
decision to treat has to be individualized” (2004:9ff). However, among other
details, the document still lists “ongoing and untreated alcohol or drug abuse” as
one of the general contraindications for HCV treatment.
REFERENCES
1. Remis RS, Hogg RS, Krahn MD, Preiksaitis JK, Sherman M. Estimating the Number
of Blood Transfusion Recipients Infected by Hepatitis C in Canada, 1960–1985 and
1990–1992. Ottawa, Ontario, Canada: Laboratory Centre for Disease Control; 1998.
2. Alter MJ, Kruszon-Moran D, Nainan OV, et al. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. New Engl J Med. 1999;341:556–562.
3. Alter MJ. The epidemiology of acute and chronic hepatitis C. Clin Liver Dis. 1997;1:559–568.
4. Zou S, Tepper M, Giulivi A. Current status of hepatitis C in Canada. Can J Public
Health. 2000;91:S10–S15.
5. Patrick D, Buxton J, Bigham M, Mathias R. Public health and hepatitis C. Can J Public
Health. 2000;91:S18–S21.
6. World Health Organization. The world health report 1998—life in the 21st century:
a vision for all. Wkly Epidemiol Record. 1998;73:145–152.
7. Alter MJ, Margolis HS, Krawczynski K, et al. The natural history of communityacquired hepatitis C in the United States. N Engl J Med. 1992;327:1899–1905.
8. Seeff LB. Natural history of hepatitis C. Hepatology. 1997;26:21S–28S.
9. Zou S, Forrester L, Giulivi A. Hepatitis C update. Can J Public Health. 2003;94:127–129.
10. Zou S, Teppe M, ElSaadany S. Prediction of hepatitis C burden in Canada. Can J Gastroenterol. 2000;14:575–580.
11. Wong JB, McQuillan GM, McHutchison JG, Poynard T. Estimating future hepatitis C morbidity, mortality and costs in the United States. Am J Public Health. 2000;90:1562–1569.
12. Cherubin CE, Sapira JD. The medical complications of drug addiction and the
medical assessment of the intravenous drug user: 25 years later. Ann Intern Med.
1993;119:1017–1028.
INJECTION DRUG USE AND HEPATITIS C
441
13. Flamm SL, Parker RA, Chopra S. Risk factors associated with chronic hepatitis C virus
infection: limited frequency of an unidentified source of transmission. Am J Gastroenterol. 1998;93:597–600.
14. Conry-Cantilena C, VanRaden M, Gibble J, et al. Routes of infection, viremia, and liver
disease in blood donors found to have hepatitis C virus infection. N Engl J Med.
1996;334:1691–1696.
15. Tortu S, Neaigus A, McMahon J, Hagen D. Hepatitis C among noninjecting drug users:
a report. Subst Use Misuse. 2001;36:523–534.
16. Harsch HH, Pankiewicz J, Bloom AS, et al. Hepatitis C virus infection in cocaine users—
a silent epidemic. Community Mental Health J. 2000;36:225–233.
17. Strader DB. Understudied populations with hepatitis C. Hepatology. 2002;36:S226–S236.
18. Hagan H. Hepatitis C virus transmission dynamics in injection drug users. Subst Use
Misuse. 1998;35:1197–1212.
19. Kelen GD, Green GB, Purcell RH, et al. Hepatitis B and hepatitis C in emergency department patients. N Engl J Med. 1992;326:1399–1404.
20. Crofts N, Hopper JL, Bowden DS, Breschkin AM, Milner R, Locarnini SA. Hepatitis C
virus infection among a cohort of Victorian injecting drug users. Med J Aust. 1993;
59:237–241.
21. Coppola RC, Masia G, di Martino ML, et al. Sexual behaviour and multiple infections in
drug abusers. Eur J Epidemiol. 1996;12:429–435.
22. Diamantis I, Bassetti S, Erb P, Ladewig D, Gyr K, Battegay M. High prevalence and coinfection rate of hepatitis G and C infections in intravenous drug addicts. J Hepatol.
1997;26:794–797.
23. Garfein R, Doherty MC, Monterroso ER, Thomas DL, Nelson K, Vlahov D. Prevalence
and incidence of hepatitis C virus infection among young adult injection drug users.
J Acquir Immun Defic Syndr. 1998;18:S11–S19.
24. Palitzsch KD, Hottentrager B, Schlottman K, et al. Prevalence of antibodies against hepatitis
C virus in the adult German population. Eur J Gastroenterol Hepatol. 1999;11:1215–1220.
25. Fugslang T, Fouchard JR, Ege PP. Prevalence of HIV and hepatitis B and C among drug
addicts in the city of Copenhagen. Ugeskr Laeger. 2000;162:3860–3864.
26. Denis B, Dedobbeleer M, Collet T, et al. High prevalence of hepatitis virus infection in
Belgian intravenous drug users and potential role of the “cotton-filter” in transmission:
the GEMT study. Acta Gastroenterol Belg. 2000;63:147–153.
27. Hagan H, Thiede H, Weiss NS, Hopkins SG, Duchin J, Alexander ER. Sharing of drug
preparation equipment as a risk factor for hepatitis C. Am J Public Health.
2001;91:42–46.
28. Diaz T, Des Jarlais D, Vlahov D, et al. Factors associated with prevalent hepatitis C:
differences among young adult injection drug users in lower and upper Manhattan,
New York City. Am J Public Health. 2001;91:23–30.
29. Fischer B, Rehm J, Baliunas D, et al. OPICAN Toronto site: Baseline data overview.
Paper presented at: IHRT All-Projects Conference; Sept. 28–29, 2002; Toronto, Ontario,
Canada.
30. Patrick D, Tyndall M, Cornelisse P, et al. Incidence of hepatitis C virus infection among
injection drug users during an outbreak of HIV infection. CMAJ. 2001;165:889–895.
31. Lamothe F, Vincelette J, Bruneau J, et al. Prevalence, seroconversion rates and risk factors for hepatitis B core, hepatitis C and HIV antibodies among intravenous drug users
(IDU) of the Saint-Luc Cohort (abstract 221). 6th Annual Canadian Conference on HIV/
AIDS Research, May 1997. Can J Infect Dis. 1997;:28A.
32. Fischer B, Medved W, Gliksman L, Rehm J. Illicit opiates in Toronto: a profile of current
users. Addict Res Theory. 1999;7:377–415.
33. Miller CL, Spittal PM, Laliberte N, Li K, O’Shaughnessy M, Schechter M. Risk factors
for HIV and HCV prevalence and incidence among young injection drug users in a
Canadian city coping with an epidemic. Paper presented at: 11th Annual Canadian
Conference on HIV/AIDS Research; April 25–28, 2002; Winnipeg, Manitoba, Canada.
442
FISCHER ET AL.
34. Poulin C, Single E, Fralick P. Canadian Community Epidemiology Network on Drug
Use (CCENDU): Second National Report. Ottawa, Ontario, Canada: Canadian Centre
on Substance Abuse; 1999.
35. Serfaty MA, Lawrie A, Smith B, et al. Risk factors and medical follow-up of drug users
tested for hepatitis C—can the risk of transmission be reduced? Drug Alcohol Rev.
1997;16:339–347.
36. Meili D, Marcinko J, Bertisch-Moellenhoff B, et al. Possible transmission routes of
viral diseases during communal preparation of drugs for i.v. use. Suchttherapie.
2002;3:S20–S26.
37. Hahn JA, Page-Shafer K, Lum PJ, et al. Hepatitis C virus seroconversion among young
injection drug users: relationships and risks. J Infect Dis. 2002;186:1558–1564.
38. Bourgois P, Bruneau J. Needle exchange, HIV infection, and the politics of science:
confronting Canada’s cocaine injection epidemic with participant observation. Med
Anthropol. 2000;18:325–350.
39. Short L, Bell D. Risk of occupational infection with blood-borne pathogens in operating
and delivery-room settings. Am J Infect Control. 1993;21:343–350.
40. Moss AR, Hahn JA. Invited commentary: needle exchange—no help for hepatitis?
Am J Epidemiol. 1999;149:214–216.
41. Wood E, Tyndall MW, Spittal PM, et al. Unsafe injection practices in a cohort of
injection drug users in Vancouver: could safer injecting rooms help? CMAJ. 2001;
165:405–410.
42. Thomas DL, Vlahov D, Solomon L, et al. Correlates of hepatitis C virus infections
among injection drug users. Medicine. 1995;74:212–220.
43. Porter J, Bonilla L, Drucker E. Methods of smoking crack as a potential risk factor for
HIV infection: crack smokers’ perceptions and behavior. Contemp Drug Probl.
1997;24:219–347.
44. Archibald CP, Ofner M, Strathdee SA, et al. Factors associated with frequent needle
exchange program attendance in injection drug users in Vancouver, Canada. J Acquir
Immune Defic Syndr. 1998;17:160–166.
45. Kwiatkowski CF, Corsi KF, Booth RE. The association between knowledge of hepatitis
C virus status and risk behaviors in injection drug users. Addiction. 2002;97:1289–1294.
46. Davis GL, Esteban-Mur R, Rustgi VK, et al. Interferon alfa-2b alone or in combination
with ribavirin for the treatment of relapse of chronic hepatitis C. N Engl J Med.
1998;339:1493–1499.
47. Diepolder HM, Zachoval R, Hoffmann RM, Junge MC, Gerlach T, Pape GR. The role
of hepatitis C virus specific CD4+ lymphocytes in acute and chronic hepatitis. J Mol Med.
1996;74:583–588.
48. Tubaro E, Santiangeli C, Belogi L, et al. Methadone versus morphine: comparison of
their effect on phagocytic functions. Int J Immunopharmacol. 1987;9:79–88.
49. Cushman P, Gupta S, Grieco MH. Immunological studies in methadone maintained
patients. Int J Addict. 1977;12:241–253.
50. Pellegrino T, Bayer BM. In vivo effects of cocaine on immune cell function. J Neuroimmunol. 1998;83:139–147.
51. Roy E, Haley N, Leclerc P, Boivin J-F, Cedras L, Vincelette J. Risk factors for hepatitis C
virus infection among street youths. CMAJ. 2001;165:557–560.
52. Mehta S, Cox A, Hoover D, et al. Protection against persistence of hepatitis C. Lancet.
2002;359:1478–1483.
53. Dore G, Freeman A, Kaldor J. Immunity against hepatitis C virus infection. Lancet.
2002;360:1019–1020.
54. Post J, Freeman A, Harvey C, French R, Lloyd A. Immunity against hepatitis C virus
infection. Lancet. 2002;360:1020.
55. El-Serag H, Bhupinderjut A, Richardson P, Rabeneck L. Association between hepatitis C
infection and other infectious diseases: a case for targeted screening? Am J Gastroenterol.
2003;98:167–174.
INJECTION DRUG USE AND HEPATITIS C
443
56. Thomas DL. Hepatitis C and human immunodeficiency virus infection. Hepatology.
2002;36:S201–S209.
57. Sulkowski MS, Mast EE, Seeff LB, Thomas DL. Hepatitis C virus infection as an opportunistic disease in persons infected with human immunodeficiency virus. Clin Infect Dis.
2000;30:S77–S84.
58. Vento S, Cainelli F. Does hepatitis C virus cause severe liver disease only in people who
drink alcohol? Lancet Infect Dis. 2002;2:303–309.
59. Dieperink E, Willenbring M, Ho SB. Neuropsychiatric symptoms associated with hepatitis C and interferon alpha: a review. Am J Psychiatry. 2000;157:867–876.
60. Booth RE, Kwiatkowski CF, Chitwood DD. Sex related HIV risk behaviors: differential
risks among injection drug users, crack smokers, and injection drug users who smoke
crack. Drug Alcohol Depend. 2000;58:219–226.
61. Ottaway CA, Erickson PG. Frequent medical visits by cocaine-using subjects in a Canadian
community: an invisible problem for health practitioners? J Subst Abuse Treat.
1997;14:423–429.
62. Palepu A, Strathdee SA, Hogg RS, et al. The social determinants of emergency department
and hospital use by injection drug users in Canada. J Urban Health. 1999;76:409–418.
63. Terrault NA. Sexual activity as a risk factor for hepatitis C. Hepatology. 2002;36:S99–S105.
64. Romanowski B, Preiksaitis J, Campbell P, Fenton J. Hepatitis C seroprevalence and risk
behaviors in patients attending sexually transmitted disease clinics. Sex Transm Dis.
2003;30:33–38.
65. Fuller CM, Vlahov D, Ompad DC, Shah N, Arria A, Strathdee SA. High-risk behaviors
associated with transition from illicit non-injection to injection drug use among adolescent and young adult drug users: a case–control study. Drug Alcohol Depend.
2002;66:189–198.
66. Myers T, Millson M, Rigby J, et al. A comparison of the determinants of safe injecting
and condom use among injecting drug users. Addiction. 1995;90:217–226.
67. Inciardi JA. The Miami sex-for-crack market. In: Ratner MS, ed. Crack Pipe as Pimp: an
Ethnographic Investigation of Sex-for-Crack Exchanges. New York: Lexington Books;
1993:36–68.
68. Hwang L-Y, Ross MW, Zack C, Bull L, Rickman K, Holleman M. Prevalence of sexually
transmitted infections and associated risk factors among populations of drug abusers.
Clin Infect Dis. 2000;31:920–926.
69. Haydon E, Fischer B, Strike C, Rehm J, Millson P. Crack Use and Hepatitis C in Canada:
a Review of Research Evidence and Questions. Ottawa, Ontario, Canada: Health
Canada; 2002.
70. Evans R, Barer M, Marmor T. Why Are Some People Healthy and Others Not? New
York: A. de Gruyter; 1994.
71. Canadian HIV/AIDS Legal Network. Injection Drug Use and HIV: Legal and Ethical
Issues. Montreal, Quebec, Canada: Canadian HIV/AIDS Legal Network; 1999.
72. Page-Shafer KA, Cahoon-Young B, Klausner JD, et al. Hepatitis C virus infection in
young, low-income women: the role of sexually transmitted infection as a potential
cofactor for HCV infection. Am J Public Health. 2002;92:670–676.
73. Logan TK, Leukefeld C. Sexual and drug use behaviors among female crack uers:
a multi-site sample. Drug Alcohol Depend. 2000;58:237–245.
74. Schroeder JR, Latkin CA, Hoover DR, Curry AD, Knowlton AR, Celetano DD. Illicit
drug use in one’s social network and in one’s neighborhood predicts individual heroin
and cocaine use. Ann Epidemiol. 2001;11:389–394.
75. Lovell AM. Risking risk: the influence of types of capital and social networks on the
injection practices of drug users. Soc Sci Med. 2002;55:803–821.
76. Mandell W, Vlahov D, Latkin C, Oziemkowska M, Cohn S. Correlates of needle sharing
among injection drug users. Am J Public Health. 1994;84:920–924.
77. Sherman S, Latkin C, Gielen A. Social factors related to syringe sharing among injecting
partners: a focus on gender. Subst Use Misuse. 2001;36:2113–2136.
444
FISCHER ET AL.
78. Patrick D, Strathdee SA, Archibald CP, et al. Determinants of HIV seroconversion in
injection drug users during a period of rising prevalence in Vancouver. Int J STD AIDS.
1997;8:437–445.
79. Harvey E, Strathdee S, Patrick D, et al. A qualitative investigation into an HIV outbreak among injection drug users in Vancouver, British Columbia. AIDS Care.
1998;10:313–321.
80. Latkin CA, Mandell W, Vlahov D, Oziemkowska M, Celetano DD. People and places:
behavioral settings and personal network characteristics as correlates of needle sharing.
J Acquir Immun Defic Syndr. 1996;13:273–280.
81. Strathdee S, Patrick D, Archibald CP, et al. Social determinants predict needle-sharing
behaviour among injection drug users in Vancouver, Canada. Addiction.
1997;92:1339–1347.
82. Estrada AL. Epidemiology of HIV/AIDS, hepatitis B, hepatitis C and tuberculosis among
minority injection drug users. Public Health Rep. 2002;117:S126–S134.
83. Craib KJP, Spittal PM, Wood E, et al. Risk factors for elevated HIV incidence among
Aboriginal injection drug users in Vancouver. CMAJ. 2003;68:19–24.
84. Zeuzem S, Feinman SV, Rasenack J, et al. Peginterferon alfa-2a in patients with chronic
hepatitis C. N Engl J Med. 2000;343:1666–1672.
85. Fried M, Shiffman M, Reddy K, et al. Peginterferon alfa-2a plus ribavirin for chronic
hepatitis C virus infection. N Engl J Med. 2002;347:975–982.
86. Nolte FS. Hepatitis C virus genotyping: clinical implications and methods. Mol Diagn.
2001;6:265–277.
87. Chaudhary RK, Tepper M, Eisaadany S, Gully PR. Distribution of hepatitis C genotypes
in Canada: results from the LCDC sentinel health unit surveillance system. Can J Infect
Dis. 1999;10:53–56.
88. Kleter B, Brouwer JT, Nevens F, et al. Hepatitis C virus genotypes: epidemiological and
clinical associations. Liver. 1998;18:32–38.
89. Bourlière M, Barberin JM, Rotily M, et al. Epidemiological changes in hepatitis C virus
genotypes in France: evidence in intravenous drug users. J Viral Hepat. 2002;9:62–70.
90. Andonov A, Chaudhary RK. Genotyping of Canadian hepatitis C virus isolates by PCR.
J Clin Microbiol. 1994;32:2031–2034.
91. Abraham HD, Degli-Esposti S, Marino L. Seroprevalence of hepatitis C in a sample of
middle class substance abusers. J Addict Dis. 1999;18:77–87.
92. Ramalho R, Costa A, Pires A, et al. Correlation of genotypes and route of transmission
with histologic activity and disease stage in chronic hepatitis C. Dig Dis Sci. 2000;
45:182–187.
93. Poynard T, Marcellin P, Lee SS, et al. Randomised trial of interferon alpha2b plus ribavirin
for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for
treatment of chronic infection with hepatitis C virus. Lancet. 1998;352:1426–1432.
94. Fried MW, Shiffman ML, Reddy RK, et al. Pegylated (40 kDa) interferon alfa-2a (Pegasys)
in combination with ribavirin: efficacy and safety results from a phase III, randomised,
actively controlled, multi-center study. Gastroenterology. 2001;5:55.
95. Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin
compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis
C: a randomised trial. Lancet. 2001;358:958–965.
96. Neuman MG, Monteiro M, Rehm J. Drug interactions between psychoactive substances
and antiretroviral therapy in individuals infected with human immunodeficiency and
hepatitis C viruses. AIDS. In press.
97. Bhattacharya R, Shuhart M. Hepatitis C and alcohol: interactions, outcomes and implications. J Clin Gastroenterol. 2003;36:242–252.
98. Mueser K, Yarnold P, Bellack A. Diagnostic and demographic correlates of substance
abuse in schizophrenia and major affective disorder. Acta Psychiatr Scand. 1992;85:48–55.
99. Brown R, Monti P, Myers M, et al. Depression among cocaine abusers in treatment: relation
to cocaine and alcohol use and treatment outcome. Am J Psychiatry. 1998;155:220–225.
INJECTION DRUG USE AND HEPATITIS C
445
100. Flynn P, Craddock S, Luckey J, Hubbard R, Dunteman G. Comorbidity of antisocial
personality and mood disorders among psychoactive substance-dependent treatment
clients. J Personal Disord. 1996;10:56–67.
101. Weiss R, Martinez-Raga J, Hufford C. The significance of a coexisting opioid use disorder in cocaine dependence: an empirical study. Am J Drug Alcohol Abuse. 1996;
22:173–184.
102. Magura S, Kang S-Y, Nwakeze P, Demsky S. Temporal patterns of heroin and cocaine
use among methadone patients. Subst Use Misuse. 1998;33:2441–2467.
103. Krausz M, Degkwitz P, Kuhne A, Verthein U. Comorbidity of opiate dependence and
mental disorders. Addict Behav. 1998;23:767–783.
104. Marlowe D, Husband S, Lamb R, Kirby K, Iguchi M, Platt J. Psychiatric comorbidity in
cocaine dependence. Diverging trends, axis II spectrum, and gender differentials.
Am J Addict. 1995;4:70–81.
105. Khantzian E. The self-medication hypothesis of addictive disorders: focus on heroin and
cocaine dependence. Am J Psychiatry. 1985;142:1264.
106. Murphy S, Khantzian E. Addiction as a “self-medication” disorder: application of ego
psychology to the treatment of substance abuse. In: Washton A, ed. Psychotherapy and
Substance Abuse: a Practitioner’s Handbook. London: Guilford Press; 1995:161–175.
107. Khantzian E. The self-medication hypothesis of substance use disorders: a reconsideration and recent applications. Harv Rev Psychiatry. 1997;4:231–224.
108. Gutfreund KS, Bain VG. Chronic viral hepatitis C: management update. CMAJ.
2000;162:827–833.
109. Crofts N, Louie R, Loff B. The next plague: stigmatization and discrimination related
to hepatitis C virus infection in Australia. Health Hum Rights. 1997;2:2.
110. Treloar CJ, Hopwood MN, Loveday SK. Hepatitis C-related discrimination in healthcare. Med J Aust. 2002;177:233–234.
111. Hagan H, Snyder N, Hough E, et alet al. Case-reporting of acute hepatitis B and C
among injection drug users. J Urban Health. 2002;79:579–585.
112. Edlin BR, Seal KH, Lorvick J, et al. Is it justifiable to withhold treatment for hepatitis C
from illicit-drug users? N Engl J Med. 2001;345:211–214.
113. National Institutes of Health. Management of hepatitis C. NIH Consens Statement
Online. 1997;15:1–41.
114. Heathcote JE, Yim C, Thai Q, Sherker A. Your Personal Health Series (Canadian Medical
Association): Hepatitis C. Toronto, Ontario, Canada: Key Porter Books; 2001.
115. Fleming CA, Craven DE, Thornton D, Tumilty S, Nunes D. Hepatitis C virus and
human immunodeficiency virus coinfection in an urban population: low eligibility for
interferon treatment. Clin Infect Dis. 2003;36:97–100.
116. Huber M, Schmid P, Vernazza P, Meili D. Reasons for the lack of treatment of hepatitis C
infection in drug dependent patients in opiate substitution. Suchttherapie. 2002;3:S27–S30.
117. Berkman LF, Kawachi I. A historical framework for social epidemiology. In: Berkman LF,
Kawachi I, eds. Social Epidemiology. Oxford, UK: Oxford University Press; 2000:3–12.
118. Davis GL, Rodrigue JR. Treatment of chronic hepatitis C in active drug users. Engl
J Med. 2001;345:215–217.
119. Di Bisceglie AM, Hoofnagle JH. Optimal therapy of hepatitis C. Hepatology. 2002;
36:S121–S127.
120. Chander G, Sulkowski MS, Jenckes MW, et al. Treatment of chronic hepatitis C:
a systematic review. Hepatology. 2002;36:S135–S144.
121. Schaefer M. Neuro-psychiatric side effects of interferon-alpha in drug addicts: reasons,
frequency and therapy. Suchttherapie. 2002;3:S72–S77.
122. National Institutes of Health. Management of Hepatitis C: Final Statement. Washington,
DC: National Institutes of Health; 2002.
123. Siebert U, Sroczynski G, Rossol S, et al. Cost effectiveness of peginterferon-2b plus ribavirin versus interferon-2b plus ribavirin for initial treatment of chronic hepatitis C.
Gut. 2003;52:425–432.
446
FISCHER ET AL.
124. Salomon J, Weinstein M, Hammitt J, Goldie S. Cost-effectiveness of treatment for
chronic hepatitis C infection in an evolving patient population. JAMA.
2003;290:228–237.
125. Sagmeister M, Wong JB, Mullhaupt B, Renner EL. A pragmatic and cost-effective strategy
of a combination therapy of interferon alpha-2b and ribavirin for the treatment of
chronic hepatitis C. Eur J Gastroenterol Hepatol. 2001;13:483–488.
126. Backmund M. Interferon therapy and detoxification treatment. Suchttherapie.
2002;3:S67–S71.
127. Backmund M, Meyer K, von Zielonka M, Eichenlaub D. Treatment of hepatitis C
infection in injection drug users. Hepatology. 2001;34:188–193.
128. Neri S, Bruno CM, Abate G, et al. Controlled clinical trial to assess the response of
recent heroin abusers with chronic hepatitis C virus infection to treatment with interferon alpha-n2b. Clin Ther. 2002;24:1627–1635.
129. Schaefer M, Schmidt F, Folwaczny C, et al. Adherence and mental side effects during
hepatitis C treatment with interferon alfa and ribavirin in psychiatric risk groups.
Hepatology. 2003;37:443–451.
130. Sylvestre DL. Treating hepatitis C in methadone maintenance patients: an interim analysis.
Drug Alcohol Depend. 2002;67:117–123.
131. Dalgard O, Bjoro K, Hellum K, et al. Treatment of chronic hepatitis C in injection drug
users: 5 years’ follow-up. Eur Addict Res. 2002;8:45–49.
132. Bickel W, Vuchinich R. Reframing Health Behavior Change With Behavioral Economics.
Mahwah, NJ: Erlbaum; 2000.
133. World Health Organization. The World Health Report 2002: Reducing Risks, Promoting
Healthy Life. Geneva, Switzerland: World Health Organization; 2002.
134. Stein M, Maksad J, Clarke J. Hepatitis C disease among injection drug users: knowledge, perceived risk and willingness to receive treatment. Drug Alcohol Depend.
2001;61:211–215.
135. Edlin BR. Prevention and treatment of hepatitis C in injection drug users. Hepatology.
2002;36:S210–S219.
136. Strathdee S, van Ameijden EJ, Mesquita F, Wodak A, Rana S, Vlahov D. Can HIV
epidemics among injection drug users be prevented? AIDS. 1998;12:S71–S79.
137. Broadhead RS, Heckathorn DD, Weakliem DL, et al. Harnessing peer networks as an
instrument for AIDS prevention: results from a peer-driven intervention. Public Health
Rep. 1998;113:42–57.
138. Fischer B, Rehm J, Blitz-Miller T. Injection drug use and preventive measures:
a comparison of Canadian and Western European jurisdictions over time. CMAJ.
2000;162:1709–1713.
139. Brands J, Brands B, Marsh D. The expansion of methadone prescribing in Ontario,
1996–1997. Addict Res Theory. 2000;8:485–496.
140. McHutchison JG, Manns M, Patel K, et al. Adherence to combination therapy enhances
sustained response in genotype-1-infected patients with chronic hepatitis C. Gastroenterology. 2002;123:1061–1069.
141. Marco A, Cayla JA, Serra M, et al. Predictors of adherence to tuberculosis treatment in
a supervised therapy programme for prisoners before and after release. Eur Respirol J.
1998;12:967–971.
142. Gourevitch MN, Wasserman W, Panero MS, Selwyn PA. Successful adherence to
observed prophylaxis and treatment of tuberculosis among drug users in a methadone
program. J Addict Dis. 1996;15:93–104.
143. Renault P, Hoofnagle JH, Park Y, et al. Psychiatric complications of long-term interferon alfa therapy. Arch Intern Med. 1987;147:1577–1580.
144. Fried MW. Side effects of therapy of hepatitis C and their management. Hepatology.
2002;36:S237–S244.
145. Frei A, Rehm J. Die Prävalenz psychischer Komorbidität unter Opiatabhängigen: eine
Metaanalyse bisheriger Studien. Psychiatr Prax. 2002;29:258–262.
INJECTION DRUG USE AND HEPATITIS C
447
146. Van Thiel DH, Friedlander L, De Maria N, Molloy PJ, Kania RJ, Colantoni A. Treatment of chronic hepatitis C in individuals with pre-existing or confounding neuropsychiatric disease. Hepatogastroenterology. 1998;45:328–330.
147. Musselman DL, Lawson DH, Gunnick JF, et al. Paroxetine for the prevention of
depression induced by high-dose interferon alfa. N Engl J Med. 2001;344:961–966.
148. Kraus MR, Schafer A, Scheurlen M, Miller AH, Musselman DL, Nemeroff CB. Paroxetine for the prevention of depression induced by high-dose interferon alfa. N Engl
J Med. 2001;345:375–376.
149. Leshner A. Addiction is a brain disease, and it matters. Science. 1997;278:45–47.
150. Hagan H, DesJarlais DC, Freidman SR, Purchase D, Alter M.J. Reduced risk of hepatitis
B and hepatitis C among injection drug users in the Tacoma syringe exchange program.
Am J Public Health. 1995;85:1531–1537.
151. Trautmann F. Peer support as a method of risk reduction in injection drug-user communities: experiences in Dutch projects and the “European peer support project.” J Drug
Issues. 1995;25:617–628.
152. Hankins C. Syringe exchange in Canada: good but not enough to stem the HIV tide.
Subst Use Misuse. 1998;33:1129–1145.
153. Fischer B, Rehm J, Kim G, Robins A. Safer injection facilities (SIFs) for injection drug
users (IDUs) in Canada: a review and call for an evidence-focused pilot trial. Can J Public
Health. 2002;93:336–338.
154. Dolan K, Kimber J, Fry C, Fitzgerald J, McDonald D, Trautmann F. Drug consumption
facilities in Europe and the establishment of supervised injecting centres in Australia.
Drug Alcohol Rev. 2000;19:337–346.
155. Heimer R, Clair S, Grau LE, et al. Hepatitis-related knowledge is low and risks are high
among HIV-aware injection drug users in three US cities. Addiction. 2002;97:1277–1287.
156. Sorensen JL, Copeland AL. Drug abuse treatment as an HIV prevention strategy. Drug
Alcohol Depend. 2000;59:17–31.
157. Marsch L. The efficacy of methadone maintenance interventions in reducing opiate use,
HIV risk behavior and criminality: a meta-analysis. Addiction. 1998;93:515–532.
158. Woodward A, Kawachi, I. Why reduce health inequalities? J Epidemiol Community
Health. 2000;54:923–929.
159. Link BG, Phelan J. Social conditions as fundamental causes of disease. J Health Soc
Behav. 1995;35:80–94.
160. EMCDDA European Monitoring Centre for Drugs and Drug Addiction. Study on
Assistance to Drug Users in Prisons. Lisbon, Portugal: European Monitoring Centre for
Drugs and Drug Addiction; 2001.
161. Glannon W. Responsibility, alcoholism, and liver transplantation. J Med Philos.
1998;23:31–49.
162. Caplan AL. Ethics of casting the first stone: personal responsibility, rationing and transplants. Alcohol Clin Exp Res. 1994;18:219–221.
163. Rehm J, Fischer B, Haydon E, Room R. Abstinence ideology and somatic treatment for
addicts—ethical considerations. Addict Res Theory. 2003;11:287–293.
164. Remis R. Estimating the incidence and prevalence of hepatitis C in Canada. Presented
at the Second Canadian Conference on Hepatitis C: New Knowledge, New Hope,
Vancouver, BC, March 27–30, 2004.
165. Sherman M, Bain V, Villeneuve J-P, et al. Management of Viral Hepatitis: A Canadian
Consensus Conference. Toronto; 2004.